This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
If cannabis is reclassified to Schedule III, cannabis businesses won't be encumbered by onerous operating and taxing obstacles, federally-funded cannabis research will finally occur, and investment will soar, writes Steve Schain.
The company’s cannabis data library includes cannabinoid and terpene strain profiles from the Leafly-Certified Labs Program, subjective strain effects from consumer reviews, and cannabis popularity metrics.
Caliper Foods recently completed a clinical research study in partnership with Colorado State University that showed that formulation design makes a significant difference in CBD pharmacokinetics.
Vertosa has entered into a research partnership with the University of Massachusetts Amherst to support the university’s studies regarding the nutritional applications and diet interactions of CBG.
Industry leaders recently convened in Denver for the first in-person Cannabis Products Exchange, offering insight into the opportunities and challenges facing the cannabis-infused food and beverage market.
Cannabis Products Exchange 2022 will kick off in person for the first time Thursday with presentations from the cannabis food and beverage industry’s leading experts.
In the first half of 2022, Radicle Science will continue to conduct rigorous clinical trials on CBD products while also commencing on blinded, randomized, placebo-controlled clinical trials on rare cannabinoids.
Initial findings of the Radicle ACES (Advancing CBD Education and Science) study indicate a significant number of participants experienced clinically meaningful improvements.